This is an aggregated industry headline. Read the full story at STAT News →
STAT+: Novartis, Novo Nordisk drug failures will likely 'pop a hole in the balloon' of the field
The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines. They could also have a chilling effect across the industry.
By STAT News
· Sep 11, 2026
· via STAT News
Image: STAT News
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekBriefing
The government released 2027 Medicare Advantage quality ratings, and early coverage singled out Humana as the …
The WeekPharmaceutical Technology ↗
Perceptive Discovery and Nucleus RadioPharma have announced a non-exclusive strategic partnership to assist ra…
The WeekAJMC ↗
Using Complement Inhibitors in GA Comes With Pros and Cons…